2022 American Transplant Congress
The Impact of Soluble Human Leukocyte Antigen (HLA) on Renal Antibody-Mediated Rejection (AMR) After Simultaneous Liver Kidney Transplantation (SLKT)
1Mayo Clinic, Phoenix, AZ, 2St. Joseph's Hospital and Medical Center, Phoenix, AZ
*Purpose: The lower incidence of AMR and higher incidence of rejection-free grafts survival in SLKT recipients as compared to kidney transplant recipients have been clearly…2022 American Transplant Congress
Use of Pronase to Identify HLA Crossmatch Antibody Interference
*Purpose: Solid organ transplant centers should maintain vigilance that antibody therapies can impact HLA crossmatch results.*Methods: N/A*Results: A 46-year-old man with Mayo stage IV cardiac…2021 American Transplant Congress
The Effect of the Different Donor-Derived HLA T-Cell Epitope Targets on the Development of T Cell-Mediated Rejection After Kidney Transplantation
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: Many kidney allografts fail due to rejections caused by the donor and recipient HLA incompatibility. Recent studies have shown that HLA-DR and DQ mismatches…2021 American Transplant Congress
Precision Medicine in Renal Transplantation: Structural Biology of HLA Defines Allelic Binding of Cardinal Pathogenic Viruses in Transplantation
*Purpose: The incidence, clearance and clinical expression of viremia post-Tx are heterogeneous, complicating prediction, prognosis and therapy. We postulated that variation viral presentation related to…2021 American Transplant Congress
Investigating the HLA Alloimmune Background of the Histological Changes Suggestive of Antibody-mediated Injury in the Absence of Donor-specific Anti-HLA Antibodies
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: The histology of antibody-mediated rejection is observed frequently after kidney transplantation, but a significant percentage of the patients do not have detectable donor-specific HLA…2020 American Transplant Congress
The Impact of HLA-DQ Molecular Mismatches on De Novo Occurrence of Donor-Specific Anti-HLA Antibodies after Kidney Transplantation: An Observational Cohort Study
*Purpose: Evaluating HLA molecular mismatches (MM) instead of antigen mismatches might be a better tool to assess donor-recipient HLA incompatibility and provide a better risk…2020 American Transplant Congress
Low HLA Class I Epitope Mismatch Associated with Improved Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplantation
University of Alabama-Birmingham, Birmingham, AL
*Purpose: Antibody-mediated rejection remains the principal cause of allotransplant graft failure. Human leukocyte antigen (HLA) matching between donor and recipients significantly reduces the risk of…2020 American Transplant Congress
Calculated Panel Reactive Antibody Values Increase for Kidney Transplant Candidates with HLA-DQA and HLA-DPB Unacceptable Antigens
*Purpose: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. CPRA includes…2020 American Transplant Congress
HLA Diversity Affects Epitope Mismatch Cutoffs Utilized to Predict De Novo DSA Development and Graft Rejection in Renal Transplant Patients
*Purpose: Recent studies have investigated epitope matching in order to determine its predictive power in determining renal transplant outcomes, both in terms of de novo…2020 American Transplant Congress
HLA Specific Antibody Levels after EDTA Treatment in CDC Crossmatch Positive and Negative Sera with Known Donor-Specific Antibodies
*Purpose: Ethylenediaminetetraacetic acid (EDTA) treatment of serum samples overcomes the prozone effect that may interfere with solid phase HLA specific antibody analyses. In patients with…
- 1
- 2
- 3
- 4
- Next Page »